Literature DB >> 29565497

Bone inflammation and chronic recurrent multifocal osteomyelitis.

Z Chen1, L Cheng, G Feng.   

Abstract

Chronic recurrent multifocal osteomyelitis (CRMO) is a sporadic condition of inflammatory bone pain that occurs as recurrent flares because of osteomyelitis, which presents in the form of multiple aseptic foci. The estimated prevalence of CRMO is 1-2 per million, affecting mostly children, in the age group of 2 to 17. Main symptoms of CRMO are bone inflammation and pain, which are generally worse at night. Other symptoms seen on radiographs indicate osteolytic lesions surrounded by sclerosis, at later stages of the disease. Markers of inflammation, viz. tumor necrosis factor a and C-reactive protein are elevated in many cases. Because of similar symptoms, differential diagnosis is needed to confirm CRMO from infectious osteomyelitis, bone tumors, and other diseases. The genetic component is likely in some cases such as Majeed syndrome, deficiency of IL-1 antagonist, etc. Imaging is the essential part of diagnosing CRMO, and magnetic resonance imaging of the whole body is the most widely used and recommended method for the evaluation of multiple foci, as compared to radiography for reasons of sensitivity as well as prevention of excessive exposure of affected children to radiation. CRMO is considered an autoimmune and auto-inflammatory disorder, but its precise pathophysiology is not clear. Current treatment options are non-steroid anti-inflammatory drugs like naproxen, as the primary choice, and the bisphosphonates such as pamidronate as the second choice, to counter the symptoms and to reduce bone lesions. The surgical option is the choice for recalcitrant cases, even though recurrence may still be a problem.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29565497     DOI: 10.26355/eurrev_201803_14482

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Chronic Non-bacterial Osteomyelitis: A Review.

Authors:  Kristian Buch; Anne Cathrine Baun Thuesen; Charlotte Brøns; Peter Schwarz
Journal:  Calcif Tissue Int       Date:  2018-11-19       Impact factor: 4.333

2.  Extensive protein expression changes induced by pamidronate in RAW 264.7 cells as determined by IP-HPLC.

Authors:  Sang Shin Lee; Soung Min Kim; Yeon Sook Kim; Suk Keun Lee
Journal:  PeerJ       Date:  2020-05-21       Impact factor: 2.984

3.  Severe bilateral Legg-Calvé-Perthes resolved with pamidronate in combination with casts, physiotherapy and adductor tenotomy: a pictorial essay over 11 years.

Authors:  Lindsey Logan; Seemab Haider; Carmen Brauer; Paivi Maria Miettunen
Journal:  BMJ Case Rep       Date:  2019-09-18

4.  Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis.

Authors:  Martina Capponi; Denise Pires Marafon; Flaminia Rivosecchi; Yongdong Zhao; Manuela Pardeo; Virginia Messia; Laura Tanturri de Horatio; Paolo Tomà; Fabrizio De Benedetti; Antonella Insalaco
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-14       Impact factor: 3.054

Review 5.  Chronic recurrent multifocal osteomyelitis. A narrative and pictorial review.

Authors:  Consolato M Sergi; Elka Miller; Dina El Demellawy; Fan Shen; Mingyong Zhang
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

6.  Chronic recurrent multifocal osteomyelitis mimicking a malignant bone tumor: a case report.

Authors:  Oumnia Bencharef; Tarik Salama; Elmouhtadi Aghoutane; Redouane Elfezzazi
Journal:  Pan Afr Med J       Date:  2022-06-24

Review 7.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625

8.  Genomic Expression Profiling and Bioinformatics Analysis of Chronic Recurrent Multifocal Osteomyelitis.

Authors:  Kai Huang; Bingyuan Lin; Yiyang Liu; Qiaofeng Guo; Haiyong Ren
Journal:  Biomed Res Int       Date:  2021-02-09       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.